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Introduction
Statins lower low-density lipoprotein cholesterol levels by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity, the rate-limiting step in cholesterol synthesis. They are among the most widely used drugs worldwide for the treatment and prevention of ischaemic heart disease. Most statins are administered in the orally active β -hydroxy acid form, the exceptions being lovastatin and simvastatin, which are given as inactive lactone prodrugs. After oral administration, the fractional absorption of statin drugs ranges from 30% to >98%, and the bioavailability ranges from <5% to 60% (Neuvonen et al., 2006) . Statin drugs are eliminated primarily through the hepatobiliary route and renal excretion constitutes a minor route of elimination, except for pravastatin. Although generally well tolerated, statin drugs can cause side effects such as myopathy, whose symptoms range from benign myalgias to lifethreatening rhabdomyolysis (Neuvonen et al., 2006) . In addition, the side effects of statin drugs are frequently associated with drug-drug interactions resulting from their chronic administration to patients who are likely to be taking multiple drugs.
Previous statin transport studies have suggested that cellular uptake and excretion of these drugs is mediated by a variety of membrane transporters. Atorvastatin, lovastatin, and simvastatin have been reported to be effluxed by P-glycoprotein (P-gp) (Hochman et al., 2004; Chen et al., 2007; Kitamura et al., 2008) , whereas the involvement of P-gp on the efflux of rosuvastatin is controversial Kitamura et al., 2008) . In contrast to ATP-binding cassette (ABC) efflux transporters, which differ in their affinity for and functional transport of various statins, the exchange transporters from the solute carrier (SLC) family organic anion transporting protein (OATP) 1B1 was reported to mediate the cellular uptake of all statin drugs except fluvastatin (Kitamura et al., 2008; Ieiri et al., 2009 ).
The purpose of this study was to identify the role of the most important intestinal ABC efflux transporters, P-gp, breast cancer resistance protein (BCRP), or multidrug resistance
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This article has not been copyedited and formatted. The final version may differ from this version. Caco-2 cell clones in which the expression of P-gp, BCRP or MRP2 were silenced with lentiviral vectors containing shRNA targeted to unique mRNA sequences in each efflux transporter (Zhang et al., 2009 ). Human intestinal cell lines such as Caco-2 are widely used to study drug absorption and efflux pathways in vitro (Hidalgo, 2001; Elsby et al., 2008) . By evaluating the bidirectional permeability of acid or lactone statins in the KD cells we determined the role of various transporters on statin transport. In addition, the system permitted observation of a general distinction between acid and lactone statins in terms of their interaction with P-gp. Rosuvastatin was determined to be a substrate of various efflux transporters and additional experiments with chemical inhibitors provided complementary evidence for the involvement of P-gp, BCRP and MRP2 on rosuvastatin transport. We have shown that KD cell lines derived from Caco-2 cells constitute a valuable system for evaluating statin transport pathways. This system avoids the need to rely only on chemical inhibitors, which lack selectivity (Watanabe et al., 2005; Wang et al., 2008) , to identify transporter-mediated drug-drug interactions. It also allows investigation of efflux mechanisms that may be extremely difficult to unravel using either non-cell based models such as membrane vesicles or animal cell lines transfected with human transporters; as compared to the Caco-2 model, these systems are less representative of the physiological factors found in human intestine (Polli et al., 2001; Elsby et al., 2008; Kitamura et al., 2008) .
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where V R is the volume in the receiver chamber (mL), A is the filter surface area (1.12 cm 2 ), C 0 is the initial concentration (μM) in the donor chamber, and dC/dt is the maximum (or initial) slope of the concentration (μM) vs. time (second) curve. The slope was calculated from the interval yielding the most linear rate of transfer spanning at least 2 sampling intervals.
Kinetic analysis of rosuvastatin was performed using GraphPad Prism ® 5.02 for Windows (San Diego, CA). The active portion of B-to-A rosuvastatin transport across Caco-2 cell monolayers was isolated by subtracting the rate at 4°C from the corresponding rate at 37°C, and then the differential transport rates were fit to the Michaelis-Menten equation:
where V is the B-to-A rosuvastatin flux (pmol/cm 2 /s) at a given concentration, C, of rosuvastatin, V max is the maximal B-to-A flux, and K m is the concentration of rosuvastatin at one-half of the
This article has not been copyedited and formatted. The final version may differ from this version. Statistical analysis. The significance of differences among multiple groups was determined by one-way ANOVA followed by post hoc Tukey tests. Differences were considered statistically significant when p < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. off-target effects of the transduction process on these transporters we transduced Caco-2 cells with a viral vector containing shRNA that does not match any known human genes using the same transduction procedure. The suppression efficiency and selectivity were examined by measuring the mRNA expression of these efflux transporters using qPCR (Table 1) . In VC cells the expression of P-gp, BCRP, and MRP2 mRNA was between 70% and 100% of the levels seen in un-transduced Caco-2 cells. In the KD cells, expression of targeted transporter genes was suppressed to 20% or less of the VC, whereas expression of non-targeted transporter genes remained 60%-100% of the VC. The suppression of efflux transporter protein expression by transduction with the shRNA-containing lentivirus was confirmed by Western blot analysis (Fig. 1) .
The transporter shRNA lentivirus-transduced cells (Lane B to D) produced much less corresponding transporter proteins than the VC-transduced cells (Lane A). Function of efflux transporters in the KD cells was assessed using prototypical substrates ( 2A) . The results indicate that P-gp was the major efflux transporter responsible for atorvastatinacid efflux in this cell model, along with some contribution from both BCRP and MRP2. The decrease in atorvastatin acid efflux across transporter KD cell monolayers was mostly due to a decrease in the B-to-A transport as there was little change in the A-to-B transport compared to VC cell monolayers. Fluvastatin acid showed a similar pattern of permeability differences among the different cell lines (Fig. 2B) . It was most highly effluxed across VC cell monolayers followed by across MRP2, BCRP and P-gp KD cell monolayers. Fluvastatin acid, similarly to the other statin acids, appears to be primarily effluxed by P-gp, with BCRP and MRP2 playing minor roles in the efflux of fluvastatin acid. The decreased efflux across monolayers of P-gp KD cells was associated with a significant decrease in the B-to-A permeability, similar to the observations obtained with atorvastatin. Rosuvastatin acid was also highly effluxed in VC cells (Fig. 2C) . The B-to-A permeability coefficients and the efflux ratios for rosuvastatin acid are diminished in all three KD cell lines, compared to those in the VC cells, suggesting all three of the targeted efflux transporters play a role in excreting rosuvastatin across the apical membrane of the intestinal cells.
After dosing the lactone form, more than half of lovastatin in the receiver compartments was converted to the acid, and the drug was not effluxed in any of the cell lines (Fig. 3) . The results indicate that the efflux transporters play no significant role in lovastatin lactone transport.
In the same experiment after lovastatin lactone dosing, formation of lovastatin acid was also
This article has not been copyedited and formatted. The final version may differ from this version. monitored, and the permeability coefficients of formed lovastatin acid were high and comparable in both A-to-B and B-to-A directions (Fig. 3B ). This high permeability would likely overwhelm any contribution of efflux or uptake transporters to the absorption of lovastatin acid in this model.
Similar to lovastatin lactone, simvastatin lactone showed approximately 50% acid conversion in the receiver compartment, and no apparent efflux in any of the cell clones (Fig. 4) . Simvastatin acid showed high transport rates in both A-to-B and B-to-A directions across the monolayers of μM and a V max of 137 ± 21 pmol/cm 2 /min. The concentration and temperature dependence confirmed the involvement of a carrier-mediated efflux system(s) in rosuvastatin transport across Caco-2 monolayers. Rosuvastatin B-to-A transport was inhibited by various compounds (Fig. 6 ). Cyclosporine A (CsA), a broad inhibitor of efflux transporters; FTC, a selective inhibitor of BCRP; GF120918 an inhibitor of both P-gp and BCRP; MK571, an inhibitor of MRPs,
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Discussion
The ABC efflux transporters, P-gp, BCRP, and MRP2, located in the apical membrane of enterocytes and in the canalicular membrane of hepatocytes, play important roles in the absorption of xenobiotics and facilitate the hepatobiliary elimination of xenobiotics and/or their metabolites. In this study we used Caco-2 cells in which efflux transporters had been knocked down using shRNA (Zhang et al., 2009) , to investigate the role of efflux transporters in statin transport. Given the gene sequence specificity of RNAi silencing (Montgomery and Fire, 1998) ,
shRNA-induced transporter knockdown is expected to avoid the cross-inhibition associated with chemical inhibitors (Watanabe et al., 2005; Wang et al., 2008) . Despite the original expectation that RNAi-mediated gene silencing was specific, subsequent studies found that RNAi-mediated silencing may be associated with down-regulation of non-target genes, so called 'off-target effects' (Jackson et al., 2003) . Furthermore, in certain animal models silencing or downregulation of a transporter gene may lead to compensatory up-regulation of other genes (Chen et al., 2005b) . To determine the knockdown efficiency and nonspecific effects of RNAi silencing in the current study, we measured the expression levels of the efflux transporters at both the mRNA and protein levels by qPCR and Western blot analysis. Knockdown of the transporter of interest was confirmed by both qPCR (Table 1) and Western blot results (Fig. 1) . The qPCR analyses further revealed that up-regulation of non-target efflux transporters was virtually absent; instead, a slight down-regulation of certain non-target transporters was observed.
Because down-regulation of off-target mRNA transcripts can hardly be avoided by the in-silico design of siRNA sequences (Echeverri and Perrimon, 2006; Tschuch et al., 2008) , additional methods were proposed to reduce the off-target effects. One approach is to use 'nonspecific' or 'scrambled' siRNAs which have no physiological target as negative controls (Echeverri and Perrimon, 2006) . Another approach is to target a single mRNA of interest with a pool of several different endonuclease-prepared siRNA molecules (Kittler et al., 2005) . Furthermore, the viral-
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This article has not been copyedited and formatted. The final version may differ from this version. based shRNA approach using lenti-or retroviruses is another option for reducing off-target effects, because viral delivery can be nearly 100% efficient in almost all cell types and the level of stable shRNA expression is comparatively modest, which causes minimal off-target effects with sustained silencing of the target gene (Tschuch et al., 2008) . Therefore, in this current study we employed lentivirus-based shRNA gene silencing to generate the transporter KD cell lines, and used the cells transduced with nonspecific shRNA vector as a negative control in the transport experiments.
The large decrease in B-to-A transport of atorvastatin in P-gp KD Caco-2 cells (Fig. 1A) indicates that P-gp is an important mediator of atorvastatin efflux, an observation consistent with the conclusions of two previous studies in Caco-2 cells Hochman et al., 2004) .
The smaller reduction in BCRP and MRP2 KD Caco-2 cells suggests that these transporters play lesser roles in atorvastatin transport. In spite of in vitro evidence showing the interaction of atorvastatin with P-gp (Hochman et al., 2004; Chen et al., 2005a) , the in vivo role of P-gp in statin drug interactions remains unclear (Holtzman et al., 2006) . This is partly because atorvastatin is metabolized by CYP3A4, and drugs that interact with atorvastatin are frequently substrates/inhibitors of both P-gp and CYP3A4. Despite these limitations, numerous pharmacokinetic drug interactions associated with atorvastatin have been reported (Boyd et al., 2000; Mazzu et al., 2000; Asberg et al., 2001 ). The affinity of atorvastatin for all three intestinal luminal efflux transporters could hamper its intestinal permeation, which may explain its moderate (30%) absorption in humans despite its relatively high lipophilicity (Neuvonen et al., 2006 ).
The two other acid statins, fluvastatin acid and rosuvastatin acid, were found to be substrates for P-gp, BCRP, and MRP2 in the transporter KD Caco-2 cell system (Fig. 2 , B and C). These results agree with a study in which MRPs were reported to mediate the efflux of fluvastatin in Caco-2 cells (Lindahl et al., 2004) . As is the case with atorvastatin, fluvastatin and
This article has not been copyedited and formatted. The final version may differ from this version. rosuvastatin were identified as P-gp substrates in vitro, but evidence of their involvement in Pgp-mediated drug interactions in vivo is scarce. In fact, co-administration of these statins with the P-gp substrate digoxin did not cause clinically significant adverse reactions to either statin drugs or digoxin (Garnett et al., 1994; Martin et al., 2002) . The apparent absence of P-gp-based drug interactions might be due to the involvement of multiple efflux transporters as for atorvastatin. The report that BCRP polymorphism alters the AUC and C max but not the elimination half-life (t½) suggests that the effect of BCRP on fluvastatin and rosuvastatin pharmacokinetics occurs primarily in the intestinal mucosa during the absorption of the acid forms of the drugs (Zhang et al., 2006; Keskitalo et al., 2009a; Keskitalo et al., 2009b) .
Another similarity shared by atorvastatin, fluvastatin and rosuvastatin, the three acid statins, is the little acid-to-lactone conversion during transport. In light of a study showing that following oral administration of atorvastatin acid to healthy volunteers, atorvastatin lactone was found in plasma (Kantola et al., 1998) , our results suggest that acid statins exist predominately in the native acid form in the gastrointestinal tract, with their lactonization occuring post absorption, most likely in the liver through the CoASH-dependent and glucuronidation pathways (Prueksaritanont et al., 2002) . In contrast to the acid statins, the lactone statins (lovastatin and simvastatin) showed substantial lactone-to-acid conversion during transport as nearly equal amounts of the lactone and acid forms appeared in the receiver chambers ( Fig. 3 and Fig. 4) .
Hydrolysis of statin lactones to statin acids in Caco-2 assays appeared to involve both spontaneous chemical conversion and enzymatic processes. Since lipophilic compounds often can permeate cell membranes and show low efflux in cell monolayers, the relatively high lipophilicity of lovastatin and simvastatin (Neuvonen et al., 2006) suggests that efflux transporter activity is unlikely to be a significant barrier for these compounds, consistent with a suggestion made in a previous study (Polli et al., 2001) . Our finding that lactone statins were either nonsubstrates or weak substrates for P-gp is in agreement with other in vitro studies (Hochman et 
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CsA, a broad inhibitor of ABC efflux transporters, partially inhibited the B-to-A transport of rosuvastatin in Caco-2 cells, indicating the involvement of these transporter(s). Inhibitions by FTC and GF120918 are consistent with rosuvastatin being a substrate of BCRP. A slight inhibition by verapamil suggests that P-gp plays only a minor role in rosuvastatin transport, an observation that contrasts with results from transporter KD cells and with findings from a previous study (Kitamura et al., 2008) . The finding that the MRP inhibitor MK571 completely abolished rosuvastatin efflux was unexpected because it appears to suggest that rosuvastatin was solely transported by MRP2 in Caco-2 cells, a possibility that conflicts with evidence of BCRP involvement found in this and other studies (Zhang et al., 2006; Kitamura et al., 2008; Keskitalo et al., 2009b ). An alternative explanation is that MK571 cross-inhibits other efflux transporters as reported previously . Together, these results highlight the difficulties associated with relying only on chemical inhibitors to identify drug transporter interactions.
In conclusion, the transporter KD Caco-2 system permitted to identify the involvement of Keskitalo et al., 2008; Keskitalo et al., 2009a) . The current study demonstrates that the transporter KD Caco-2 system is a straightforward approach to assess drug-transporter interactions. Its human origin makes results relevant to human studies and avoids the species differences in statin interactions with efflux transporters that have been observed (Kitamura et al., 2008) . In addition, Caco-2 cells express a basolateral uptake system that is essential for statins to reach apical efflux transporters. Due to the absence of this basolateral uptake transporter in MDCK cells, statin efflux could not be detected in non-or single-transfected MDCK cells (Kitamura et al., 2008) . Overall, the transporter KD Caco-2 cells provide a valuable tool to study drug interactions with human transporters in vitro (Watanabe et al., 2005) .
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